<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430479</url>
  </required_header>
  <id_info>
    <org_study_id>kbcrnb002</org_study_id>
    <nct_id>NCT03430479</nct_id>
  </id_info>
  <brief_title>Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer</brief_title>
  <official_title>Phase Ib/II Study to Assess Efficacy, Safety &amp; Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto Breast Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto Breast Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and efficacy of anti PD-1 antibody with&#xD;
      radiation therapy in patients with HER2-negative metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib : dose-limiting toxicity rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort A</intervention_name>
    <description>Radiation + Nivolumab + hormone therapy</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Cohort A&#xD;
&#xD;
          1. Documentation of ER-positive and/or PR-positive tumor (&gt;=1% positive stained cells) .&#xD;
&#xD;
          2. Patients must satisfy the following criteria for prior therapy:&#xD;
&#xD;
             - Progressed during treatment or within 12 months of completion of adjuvant hormone&#xD;
             therapy.&#xD;
&#xD;
             or Progressed while prior hormone therapy for advanced/metastatic breast cancer. Two&#xD;
             previous line of hormone therapy for advanced/metastatic disease is allowed.&#xD;
&#xD;
          3. Patients who have hormone therapy that can be expected for advanced /metastatic&#xD;
             disease.&#xD;
&#xD;
             Cohort B&#xD;
&#xD;
          4. Patients who have come to be non-responsive more than two line of chemotherapy&#xD;
&#xD;
          5. Prior chemotherapy with anthracycline and taxane agent&#xD;
&#xD;
             Cohort A and B&#xD;
&#xD;
          6. Female patients who are histologically or cytologically confirmed to have breast&#xD;
             cancer&#xD;
&#xD;
          7. Patients who have distant metastatic lesion as follow&#xD;
&#xD;
             - More than one bone lesion for radiation therapy&#xD;
&#xD;
          8. Patients with cancer confirmed to be HER2-negative.（&#xD;
&#xD;
          9. Patients with a measurable lesion based on RECIST 1.1.&#xD;
&#xD;
         10. Patients aged &gt;= 20 years at informed consent&#xD;
&#xD;
         11. Patients with ECOG PS of 0 to 1.&#xD;
&#xD;
         12. Patients without any severe disorder in the major organs.&#xD;
&#xD;
         13. Patients expected to survive for ≥ 90 days.&#xD;
&#xD;
         14. Patients of childbearing potential must be using an acceptable method of contraception&#xD;
             to avoid pregnancy and must not be breastfeeding for 18 weeks after the last dose of&#xD;
             investigational product&#xD;
&#xD;
         15. Patients who have provided written informed consent themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have neuropathy (more than Grade 2)&#xD;
&#xD;
          2. Patients with any active autoimmune disease or a history of known autoimmune disease.&#xD;
&#xD;
          3. Patients who has a history of pneumonitis or interstitial lung disease.&#xD;
&#xD;
          4. Active, untreated central nervous system metastasis.&#xD;
&#xD;
          5. Patients with pericardial effusion, pleural effusion or ascites requiring treatment&#xD;
&#xD;
          6. Patients with uncontrolled diabetes mellitus&#xD;
&#xD;
          7. Patients with a condition requiring systemic treatment with either corticosteroids or&#xD;
             other immunosuppressive medications within 28 days of the enrollment.&#xD;
&#xD;
          8. Patients who has received radiotherapy within 28 days of study registration, or&#xD;
             radiotherapy for thorax within 56 days of the enrollment.&#xD;
&#xD;
          9. Pregnant or breast-feeding women.&#xD;
&#xD;
         10. Prior therapy with Nivolumab, anti CTLA-4 antibody therapies, any other antibody or&#xD;
             drug specifically targeting T-cell co-stimulation or checkpoint pathways&#xD;
&#xD;
         11. Patients considered ineligible for participation in this study by their attending&#xD;
             physicians&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

